The “Shield Sign” in Two Men with Metastatic Salivary Duct Carcinoma to the Skin: Cutaneous Metastases Presenting as Carcinoma Hemorrhagiectoides

Por Cohen, Philip R., Prieto, Victor G., Piha-Paul, Sarina A., Kurzrock, Razelle
Publicado em 2012

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus

Por Piha-Paul, Sarina A., Wheler, Jennifer J., Fu, Siqing, Levenback, Charles, Lu, Karen, Falchook, Gerald S., Naing, Aung, Hong, David S., Tsimberidou, Apostolia M., Kurzrock, Razelle
Publicado em 2014

Combining Erlotinib and Cetuximab is Associated with Activity in Patients with Non Small Cell Lung Cancer (including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutat...

Por Wheler, Jennifer J., Tsimberidou, Apostolia M., Falchook, Gerald S., Zinner, Ralph G., Hong, David S., Fok, Jansina Y., Fu, Siqing, Piha-Paul, Sarina A., Naing, Aung, Kurzrock, Razelle
Publicado em 2013

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer

Por Falchook, Gerald S., Naing, Aung, Wheler, Jennifer J., Tsimberidou, Apostolia M., Zinner, Ralph, Hong, David S., Fu, Siqing, Piha-Paul, Sarina A., Janku, Filip, Hess, Kenneth R., Bastida, Christel, Kurzrock, Razelle
Publicado no Oncoscience (2014)

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials

Por Janku, Filip, Wheler, Jennifer J., Naing, Aung, Falchook, Gerald S., Hong, David S., Stepanek, Vanda M., Fu, Siqing, Piha-Paul, Sarina A., Lee, J. Jack, Luthra, Rajyalakshmi, Tsimberidou, Apostolia M., Kurzrock, Razelle
Publicado em 2012

Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer

Por Falchook, Gerald S., Naing, Aung, Hong, David S., Zinner, Ralph, Fu, Siqing, Piha-Paul, Sarina A., Tsimberidou, Apostolia M., Morgan-Linnell, Sonia K., Jiang, Yunfang, Bastida, Christel, Wheler, Jennifer J., Kurzrock, Razelle
Publicado em 2013

Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit

Por Fu, Siqing, McQuinn, Lacey, Naing, Aung, Wheler, Jennifer J., Janku, Filip, Falchook, Gerald S., Piha-Paul, Sarina A., Tu, Dennis, Howard, Adrienne, Tsimberidou, Apostolia, Zinner, Ralph, Hong, David S., Kurzrock, Razelle
Publicado em 2013

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors

Por Falchook, Gerald S., Wheler, Jennifer J., Naing, Aung, Piha-Paul, Sarina A., Fu, Siqing, Tsimberidou, Apostolia M., Hong, David S., Janku, Filip, Zinner, Ralph, Jiang, Yunfang, Huang, Mei, Lin, Quan, Parkhurst, Kristin, Kurzrock, Razelle
Publicado no Invest New Drugs (2014)

A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer

Por Falchook, Gerald S., Moulder, Stacy, Naing, Aung, Wheler, Jennifer J., Hong, David S., Piha-Paul, Sarina A., Tsimberidou, Apostolia M., Fu, Siqing, Zinner, Ralph, Janku, Filip, Jiang, Yunfang, Huang, Mei, Parkhurst, Kristin L., Kurzrock, Razelle
Publicado no Invest New Drugs (2014)

FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors

Por Jardim, Denis L., Wheler, Jennifer J., Hess, Kenneth, Tsimberidou, Apostolia M., Zinner, Ralph, Janku, Filip, Subbiah, Vivek, Naing, Aung, Piha-Paul, Sarina A., Westin, Shannon N., Roy-Chowdhuri, Sinchita, Meric-Bernstam, Funda, Hong, David S.
Publicado em 2014

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

Por Wheler, Jennifer J., Moulder, Stacy L., Naing, Aung, Janku, Filip, Piha-Paul, Sarina A., Falchook, Gerald S., Zinner, Ralph, Tsimberidou, Apostolia M., Fu, Siqing, Hong, David S., Atkins, Johnique T., Yelensky, Roman, Stephens, Philip J., Kurzrock, Razelle
Publicado em 2014

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus

Por Liu, Xiaochun, Kambrick, Susan, Fu, Siqing, Naing, Aung, Subbiah, Vivek, Blumenschein, George R., Glisson, Bonnie S., Kies, Merrill S., Tsimberidou, Apostolia M., Wheler, Jennifer J., Zinner, Ralph G., Hong, David S., Kurzrock, Razelle, Piha-Paul, Sarina A.
Publicado no Oncotarget (2016)

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

Por Janku, Filip, Tsimberidou, Apostolia M., Garrido-Laguna, Ignacio, Wang, Xuemei, Luthra, Rajyalakshmi, Hong, David S., Naing, Aung, Falchook, Gerald S., Moroney, John W., Piha-Paul, Sarina A., Wheler, Jennifer J., Moulder, Stacy L., Fu, Siqing, Kurzrock, Razelle
Publicado em 2011

Phase I Study of Anti-VEGF Monoclonal Antibody Bevacizumab and Histone Deacetylase Inhibitor Valproic Acid in Patients with Advanced Cancers

Por Wheler, Jennifer J., Janku, Filip, Falchook, Gerald S., Jackson, Tiffiny L., Fu, Siqing, Naing, Aung, Tsimberidou, Apostalia M., Moulder, Stacy L., Hong, David S., Yang, Hui, Piha-Paul, Sarina A., Atkins, Johnique T., Garcia-Manero, Guillermo, Kurzrock, Razelle
Publicado em 2014

PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes

Por Janku, Filip, Wheler, Jennifer J., Naing, Aung, Stepanek, Vanda M., Falchook, Gerald S., Fu, Siqing, Garrido-Laguna, Ignacio, Tsimberidou, Apostolia M., Piha-Paul, Sarina A., Moulder, Stacy L., Lee, J. Jack, Luthra, Rajyalakshmi, Hong, David S., Kurzrock, Razelle
Publicado em 2012

PIK3CA, and PTEN Aberrations in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors: Experience with 1,656 Patients at MD Anderson Cancer Center

Por Janku, Filip, Hong, David S., Fu, Siqing, Piha-Paul, Sarina A., Naing, Aung, Falchook, Gerald S., Tsimberidou, Apostolia M., Stepanek, Vanda M., Moulder, Stacy L., Lee, J. Jack, Luthra, Rajyalakshmi, Zinner, Ralph G., Broaddus, Russell R., Wheler, Jennifer J., Kurzrock, Razelle
Publicado no Cell Rep (2014)

Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA mutations

Por Ganesan, Prasanth, Janku, Filip, Naing, Aung, Hong, David S., Tsimberidou, Apostolia M., Falchook, Gerald S., Wheler, Jennifer J., Piha-Paul, Sarina A., Fu, Siqing, Stepanek, Vanda M., Lee, J. Jack, Luthra, Rajyalakshmi, Overman, Michael J., Kopetz, E. Scott, Wolff, Robert A, Kurzrock, Razelle
Publicado em 2013

Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit

Por de Melo Gagliato, Debora, Fontes Jardim, Denis L., Falchook, Gerald, Tang, Chad, Zinner, Ralph, Wheler, Jennifer J., Janku, Filip, Subbiah, Vivek, Piha-Paul, Sarina A., Fu, Siqing, Hess, Kenneth, Roy-Chowdhuri, Sinchita, Moulder, Stacy, Gonzalez-Angulo, Ana M., Meric-Bernstam, Funda, Hong, David S.
Publicado no Clin Breast Cancer (2014)

MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors

Por Jardim, Denis L. F., de Melo Gagliato, Débora, Falchook, Gerald, Zinner, Ralph, Wheler, Jennifer J., Janku, Filip, Subbiah, Vivek, Piha-Paul, Sarina A., Fu, Siqing, Tannir, Nizar, Corn, Paul, Tang, Chad, Hess, Kenneth, Roy-Chowdhuri, Sinchita, Kurzrock, Razelle, Meric-Bernstam, Funda, Hong, David S.
Publicado no Clin Genitourin Cancer (2014)

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials

Por Meric-Bernstam, Funda, Brusco, Lauren, Shaw, Kenna, Horombe, Chacha, Kopetz, Scott, Davies, Michael A., Routbort, Mark, Piha-Paul, Sarina A., Janku, Filip, Ueno, Naoto, Hong, David, De Groot, John, Ravi, Vinod, Li, Yisheng, Luthra, Raja, Patel, Keyur, Broaddus, Russell, Mendelsohn, John, Mills, Gordon B.
Publicado no J Clin Oncol (2015)